JMS Co

JMS Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of JMS Co (7702.T) as of Nov 4, 2026 is 0.46 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 1.07 % — a change of -57.04% (lower).

EBIT/Assets

0.46 %

YoY

-57.04%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of JMS Co is 2026 0.46 % . Operating Income to Assets Ratio (EBIT/Assets) of JMS Co was 2025 1.07 % . It decreases by -57.04% lower compared to the previous year.

The JMS Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
2.17 JPY
Jan 1, 2020
3.74 JPY
Jan 1, 2021
3.32 JPY
Jan 1, 2022
1.36 JPY
Jan 1, 2023
0.97 JPY
Jan 1, 2024
0.43 JPY
Jan 1, 2025
1.07 JPY
Jan 1, 2026
0.46 JPY
The JMS Co EBIT/Assets history
YEAREBIT/AssetsYoY
0.46 %-57.04%
1.07 %+148.41%
0.43 %-55.60%
0.97 %-28.54%
1.36 %-58.98%
3.32 %-11.34%
3.74 %+72.14%
2.17 %+54.56%
1.41 %-16.44%
1.68 %-22.82%
2.18 %+248.93%
0.63 %-63.02%
1.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JMS Co Stock analysis

What does JMS Co do? JMS Co., Ltd. generates revenue through the manufacture, sale, export, and import of medical devices and pharmaceuticals across its five geographical segments: Japan, Singapore, China, Philippines, and Germany. The company offers a range of products including infusion and nutrition products, dialysis products, surgery products, blood and cell products, and other related items. Key products such as infusion & transfusion sets, syringe pumps, surgical gowns, dialysis kits, peritoneal dialysate, microcatheters, and blood bags are sold to healthcare providers and institutions within these regions. The firm also provides maintenance services and other related services as part of its product portfolio. The company's primary customers are healthcare providers and institutions in Japan, Singapore, China, Philippines, and Germany, where it operates through its five geographical segments. These customers purchase medical equipment and drugs, including specific items like infusion & transfusion sets, dialysis kits, and surgical gowns. The firm's product lines are tailored to meet the needs of hospitals, clinics, and other medical facilities across its operational regions. JMS Co., Ltd. focuses on manufacturing and selling medical equipment and drugs, with a strong emphasis on products such as infusion & transfusion sets, syringe pumps, surgical gowns, and dialysis kits. The company's revenue streams are driven by the sale of these products and the provision of maintenance services. Its geographical segments ensure a diversified market presence, allowing it to serve various healthcare sectors in different countries. JMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JMS Co stock

Operating Income to Assets Ratio (EBIT/Assets) of JMS Co is 0.46 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of JMS Co changed from 1.07 % to 0.46 %, representing a -57.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) JMS Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s JMS Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — JMS Co

All Key Metrics — JMS Co